There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rockwell Med (RMTI), HTG Molecular Diagnostics (HTGM) and BioCryst (BCRX) with bullish sentiments.
Rockwell Med (RMTI)
In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Rockwell Med, with a price target of $12. The company’s shares closed yesterday at $2.42, close to its 52-week low of $2.19.
Selvaraju said:
“We have valued Rockwell Medical based on a discounted cash flow (DCF)-driven assessment, which ascribes a total firm value of $735M to the company based solely on the Triferic product line in the U.S. and the company’s core dialysate franchise. We utilize a 12% discount rate and 27% effective tax rate, along with an 80% probability of regulatory approval for I.V. 1% terminal growth rate. This translates into a price per share of roughly $12, assuming approximately 63.9M total shares outstanding as of end-1Q20.”
According to TipRanks.com, Selvaraju has currently no stars on a ranking scale of 0-5 stars, with an average return of -12.2% and a 25.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries Ltd., Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Rockwell Med has an analyst consensus of Strong Buy, with a price target consensus of $11, which is a 354.5% upside from current levels. In a report issued on July 30, Piper Jaffray also reiterated a Buy rating on the stock with a $10 price target.
See today’s analyst top recommended stocks >>
HTG Molecular Diagnostics (HTGM)
H.C. Wainwright analyst Yi Chen reiterated a Buy rating on HTG Molecular Diagnostics today and set a price target of $4. The company’s shares closed yesterday at $1.38, close to its 52-week low of $1.27.
According to TipRanks.com, Chen ‘s ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -19.9% and a 32.8% success rate. Chen covers the Healthcare sector, focusing on stocks such as EyePoint Pharmaceuticals Inc, Stealth Biotherapeutics Corp, and Aerpio Pharmaceuticals Inc.
HTG Molecular Diagnostics has an analyst consensus of Strong Buy, with a price target consensus of $4.67.
BioCryst (BCRX)
In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on BioCryst, with a price target of $13. The company’s shares closed yesterday at $2.97, close to its 52-week low of $2.60.
According to TipRanks.com, Fein is a 2-star analyst with an average return of 0.4% and a 38.9% success rate. Fein covers the Healthcare sector, focusing on stocks such as Constellation Pharmaceuticals Inc, DBV Technologies SA – American, and ACADIA Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for BioCryst with a $9.58 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
